Extended indication Extension of indication to include treatment of adults with active axial spondyloarthritis (axSp
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Bimekizumab
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Rheumatism
Extended indication Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Proprietary name Bimzelx
Manufacturer UCB
Portfolio holder Incyte
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional comments Bimekizumab is a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. Vermoedelijk intramurale bekostiging vanwege het feit dat het een biological is.

Registration

Type of trajectory Normal trajectory
Submission date September 2022
Expected Registration July 2023
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 15,000.00 - 20,000.00
References Farmacotherapeutisch kompas
Additional comments Bimzelx, 1 ml injectievloeistof 160 mg/ml: € 1.202,27. Op basis van inschattingen van andere biologicals met dezelfde indicatie is de verwachting dat bimekizumab €15.000-€20.000 zal gaan kosten.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.